- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04078581
Profiling Fecal Samples for Selection of Donors of Feces (PROFIT)
Profiling Fecal Samples to Optimize Selection of Stool Donors for Fecal Microbiota Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nathalie KAPEL, PharmD, PhD
- Phone Number: +33 01 42 16 26 56
- Email: nathalie.kapel@aphp.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Healthy volunteers
- Participant having been informed of the study and having sign a consent to participation
- Patient affiliated with a social security or beneficiary of such a social protection
Exclusion Criteria:
- Person subject to legal protection (guardianship, trusteeship, etc.)
- Chronic disease that can alter the intestinal microbiota: cancer or malignant disease, bowel disease, diabetes, hypertension, hypercholesterolemia, ....
- Presence in the 1st degree family of one of the chronic diseases mentioned above
- Blood in stools
- Chronic drug treatment likely to alter the intestinal microbiota
- Travel to a tropical country in the last 3 months or extended stay (> 3 months) for less than 1 year
- Hospitalization abroad (> 24h) in the last 12 months
- Hospitalization abroad (> 24h) of a family member living under the same roof during the last 12 months
- Medical consultation in the last 3 months (other than administrative)
- Contact with a person with an infectious or contagious disease for more than 3 months
- Digestive disorders / febrile gastroenteritis (diarrhea with fever) in the last 3 months
- Febrile illnesses for more than 3 months
- Antibiotic treatment in the last 3 months
- Treatment with PPIs in the last 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: healthy controls
Questionnaire and fecal sample collection
|
Questionnaire and fecal sample collection in order to select donors for FMT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosage of fecal samples with search for differentiated fecal profiles.
Time Frame: At 12 months
|
16S genomic analysis of microbiota will be performed for the evaluation of alpha and beta diversities of microbiota. Results will be aggregated to define differentiated faecal profiles in healthy volunteers. |
At 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosage of fecal biomarkers with search for differentiated fecal profiles.
Time Frame: At 12 months
|
Fecal biomarkers such as calprotectin will be dosed.
Results will be aggregated to define differentiated faecal profiles in healthy volunteers.
|
At 12 months
|
Quantification of colonic inflammation in mouse model.
Time Frame: At 15 months
|
The quantification of colonic inflammation by myeloperoxidase assay using a sandwich ELISA enzyme-linked immunosorbent assay. Mouse model : authorization APAFlS#7600-20l60620l6336853 v3 |
At 15 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Nathalie KAPEL, PharmD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- APHP190341
- 2019-A01012-55 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Microbiota Transplantation
-
Keimyung University Dongsan Medical CenterRecruitingFecal Microbiota TransplantationKorea, Republic of
-
University Hospital of North NorwayCompletedFecal Microbiota TransplantationNorway
-
MaaT PharmaTerminatedIntensive Care Units | Fecal Microbiota TransplantationFrance
-
Shanghai 10th People's HospitalCompletedSmall Intestinal Bacterial Overgrowth | Fecal Microbiota TransplantationChina
-
Guangzhou First People's HospitalRecruitingFecal Microbiota TransplantationChina
-
Michael ScharlRecruitingCancer | Immunotherapy | Immune Checkpoint Inhibitors | Fecal Microbiota TransplantationSwitzerland
-
MaaT PharmaCompletedFecal Microbiota TransplantationFrance, Italy, Poland
-
Helsinki University Central HospitalUniversity of HelsinkiActive, not recruitingFecal Microbiota Transplantation | Cesarean Section, Affecting Fetus or Newborn | Intestinal MicrobiomeFinland
-
Shanghai 10th People's HospitalRecruiting
-
The Second Hospital of Nanjing Medical UniversityThe First Affiliated Hospital of Guangdong Pharmaceutical University; Wuxi... and other collaboratorsNot yet recruitingBowel Obstruction | Fecal Microbiota TransplantationChina
Clinical Trials on Questionnaire and fecal sample collection
-
Nemours Children's ClinicCompleted
-
University of Roma La SapienzaCompletedInflammatory Bowel DiseaseItaly
-
Nantes University HospitalTerminatedAlzheimer Disease | Intestinal MicrobiotaFrance
-
Peking Union Medical College HospitalActive, not recruitingPancreatic CancerChina
-
University Medical Center GroningenRecruitingColorectal Cancer MetastaticNetherlands
-
Association pour la Recherche Clinique et ImmunologiqueUnknown
-
Centre hospitalier de l'Université de Montréal...CompletedInflammatory Bowel Diseases | Colorectal Cancer | Anastomotic Leak | MicrobiotaCanada
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedNon Small Cell Lung Cancer | Metastatic MelanomaItaly
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Catholic University of the Sacred Heart; Institute of Biomembranes, Bioenergetics... and other collaboratorsCompletedHepatic Encephalopathy | Irritable Bowel Syndrome | Clostridium Difficile Infection | Chronic Inflammatory Bowel Disease | Multi Drug Resistant OrganismsItaly